Brief: Equillium And Ono Pharmaceutical Announce Exclusive Option And Asset Purchase Agreement For Development And Commercialization Of Itolizumab

ONO PHARMACEUTICAL

06/12/2022 12:39

Dec 6 (Reuters) - Ono Pharmaceutical Co Ltd  4528.T :
    * EQUILLIUM AND ONO PHARMACEUTICAL ANNOUNCE EXCLUSIVE OPTION
AND
ASSET PURCHASE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION
OF ITOLIZUMAB
    * EQUILLIUM INC - EQUILLIUM GRANTS ONO AN OPTION TO PURCHASE
RIGHTS TO ITOLIZUMAB
    * EQUILLIUM INC - EQUILLIUM TO RECEIVE AN UPFRONT PAYMENT OF
APPROXIMATELY $26.0M (¥3.5B)
    * EQUILLIUM INC - ELIGIBLE TO RECEIVE UP TO APPROXIMATELY
$138.5M
(¥18.7B) IN OPTION EXERCISE AND MILESTONE PAYMENTS
    * EQUILLIUM INC - ONO TO FUND EQUILLIUM'S CONTINUED RESEARCH
AND
DEVELOPMENT OF ITOLIZUMAB DURING EXERCISE PERIOD

Source text for Eikon:  ID:nBw9NKf9Ga 
Further company coverage:  4528.T